For these 222 BC patients with a germline BRCA1 or BRCA2 mutation, we analyzed the association of cFTH1 (Table 2) and nFTH1 (Table 3) expression with the relevant clinicopathological variables. This evidence concerns the gene BRCA2 and breast cancer.